Global Assets Advisory LLC Makes New $443,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Global Assets Advisory LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 759 shares of the biopharmaceutical company's stock, valued at approximately $443,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the period. Sigma Planning Corp raised its holdings in shares of Regeneron Pharmaceuticals by 91.2% during the fourth quarter. Sigma Planning Corp now owns 782 shares of the biopharmaceutical company's stock worth $557,000 after acquiring an additional 373 shares during the period. IFP Advisors Inc raised its holdings in shares of Regeneron Pharmaceuticals by 17.2% during the fourth quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company's stock worth $262,000 after acquiring an additional 54 shares during the period. FourThought Financial Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $435,000. Finally, Birinyi Associates Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $1,478,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a report on Monday, June 2nd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday, April 17th. Finally, Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $822.58.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $520.29 on Thursday. The company has a market cap of $56.17 billion, a PE ratio of 13.25, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The firm has a 50-day moving average of $555.86 and a 200-day moving average of $636.54. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted $9.55 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.68%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.